Evidence map›Paper›PMID 39941103›Full record

ReviewInternational journal of molecular sciences2025

Exploiting the Molecular Properties of Fibrinogen to Control Bleeding Following Vascular Injury.

Tanjot Singh, Muhammad Hasan, Thembaninkosi G Gaule, Ramzi A Ajjan

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tanjot SinghLeeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Woodhouse, Leeds LS2 9JT, UK.ORCID 0009-0009-4129-2074
Muhammad HasanSt James's University Hospital, Beckett St, Harehills, Leeds LS9 7TF, UK.
Thembaninkosi G GauleLeeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Woodhouse, Leeds LS2 9JT, UK.
Ramzi A AjjanLeeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Woodhouse, Leeds LS2 9JT, UK.ORCID 0000-0002-1636-3725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The plasma protein fibrinogen is critical for haemostasis and wound healing, serving as the structural foundation of the blood clot. Through a complex interaction between coagulation factors, the soluble plasma fibrinogen is converted to insoluble fibrin networks, which form the skeleton of the blood clot, an essential step to limit blood loss after vascular trauma. This review examines the molecular mechanisms by which fibrinogen modulates bleeding, focusing on its interactions with other proteins that maintain fibrin network stability and prevent premature breakdown. Moreover, we also cover the role of fibrinogen in ensuring clot stability through the physiological interaction with platelets. We address the therapeutic applications of fibrinogen across various clinical contexts, including trauma-induced coagulopathy, postpartum haemorrhage, and cardiac surgery. Importantly, a full understanding of protein function will allow the development of new therapeutics to limit blood loss following vascular trauma, which remains a key cause of mortality worldwide. While current management strategies help with blood loss following vascular injury, they are far from perfect and future research should prioritise refining fibrinogen replacement strategies and developing novel agents to stabilise the fibrin network. Exploiting fibrinogen's molecular properties holds significant potential for improving outcomes in trauma care, surgical interventions and obstetric haemorrhage.

Indexed as

FibrinogenHemorrhageVascular System InjuriesAnimalsBlood CoagulationFibrinHemostasisHumansPostpartum HemorrhageFibrinFibrinogenbleeding modulationfibrinogenfibrin stabilisationhaemostasistrauma

Identifiers

PMID39941103
PMCPMC11818741

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.